Costs of Adverse Events in Patients with Advanced or Metastatic Renal Cell Carcinoma with First-Line Treatment

This study evaluated costs associated with adverse events (AEs) in previously untreated real-world patients with advanced renal cell carcinoma (aRCC) in the USA. This retrospective longitudinal cohort study analyzed data from the Merative MarketScan Research Database (1 January 2014-30 September 202...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	PharmacoEconomics - Open 2025-01, Vol.9 (1), p.125-136
Hauptverfasser:	Chen, Yan, Du, Ella X, Sundar, Manasvi, Betts, Keith A, Yin, Xin, Eiffert, Samantha, Beauchamp, Karen, Delgado, Andrew, Rosenblatt, Lisa
Format:	Artikel
Sprache:	eng
Schlagworte:	Antimitotic agents Antineoplastic agents Cancer therapies Carcinoma, Renal cell Clinical trials Combination therapy Cost control Costs Dyspnea Economic aspects Health care expenditures Health care policy Health insurance Health maintenance organizations HMOs Hypertension Hyponatremia Immunotherapy Kidney cancer Medical care, Cost of Medical research Medicine, Experimental Metastasis Monoclonal antibodies Online databases Original Pancreatitis Patients Tumors Vascular endothelial growth factor
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!